Carnosine
Also known as: beta-alanyl-L-histidine, beta-alanyl histidine, carnosine (supplement), anserine (related dipeptide)
Human trials provide mixed results. Some randomized trials report modest improvements in measures of muscular or cardiorespiratory endurance in select subgroups (younger adults or males) and preservation of certain cognitive measures in elderly subjects given anserine/carnosine mixtures. A small meta-analysis of four RCTs reported a reduction in HbA1c but no consistent effects on fasting glucose, insulin resistance or most lipid outcomes.
Last reviewed: 2026-10-14 · 5 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Carnosine is an endogenous dipeptide (β-alanyl-L-histidine) found at high concentrations in skeletal muscle and brain. Oral carnosine or combined anserine/carnosine supplements have been tested for effects on exercise endurance, aspects of cognition in older adults, and markers of glycaemic control.
Mechanism & Function
Mechanism of Action
Proposed mechanisms include intracellular proton buffering in muscle (supporting high-intensity metabolism), antioxidant and anti-inflammatory effects, and potential effects on brain perfusion. Oral carnosine is subject to hydrolysis by serum carnosinase, which affects circulating availability and may influence efficacy.
Physiological Role
Intracellular pH buffering, antioxidant activity, and modulation of inflammatory mediators in muscle and brain tissues.
Primary Pathways
Performance / Health Relevance
Carnosine's role in muscle buffering provides a plausible basis for ergogenic effects during repeated high-intensity or endurance tasks; however, circulating bioavailability after oral dosing is limited by serum carnosinase and trial results are inconsistent and subgroup-specific.
Evidence Review
Practical Use & Dosage
- Minimum Effective Dose
- Not established — clinical trials used a wide range (acute 20 mg/kg; chronic 250 mg–2 g/day depending on formulation).
- Optimal Range
- Approx. 250 mg/day to 2 g/day as used in trials (including combined anserine/carnosine products); efficacy and dose–response not well defined.
- Upper / Caution Level
- Not established from provided trials.
- Timing
- Daily dosing in chronic trials; acute dosing used prior to exercise in one study (20 mg/kg).
- Best Format
- Oral capsules/standardised powder; many trials used combined anserine/carnosine formulations.
- Bioavailability
- Oral carnosine is rapidly degraded in plasma by serum carnosinase (CN1); anserine (a related dipeptide) is less susceptible and is commonly used in combined formulations.
- Absorption Considerations
- Interindividual differences in serum carnosinase activity influence circulating carnosine after oral doses and may affect responsiveness.
Safety & Interactions
Side Effects
- •No major adverse effects reported in the provided abstracts; detailed safety data limited in these reports.
Contraindications
- Insufficient data in pregnancy and breastfeeding; not established in paediatric populations.
Drug Interactions
- •Not reported in the provided abstracts.
Who Should Avoid
- •Pregnant or breastfeeding individuals due to limited safety data.
Monitoring
None specified in the trials; consider monitoring for expected clinical endpoints if used for glycaemic control or performance.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Carnosine typically used or indicated?
Carnosine is most commonly used for: Exercise performance / endurance support, Cognitive support in older adults, Metabolic health (glycaemic control). Intracellular pH buffering, antioxidant activity, and modulation of inflammatory mediators in muscle and brain tissues.
How does Carnosine work?
Proposed mechanisms include intracellular proton buffering in muscle (supporting high-intensity metabolism), antioxidant and anti-inflammatory effects, and potential effects on brain perfusion. Oral carnosine is subject to hydrolysis by serum carnosinase, which affects circulating availability and may influence efficacy.
What is the recommended dose of Carnosine?
The optimal range is Approx. 250 mg/day to 2 g/day as used in trials (including combined anserine/carnosine products); efficacy and dose–response not well defined.. with a minimum effective dose of Not established — clinical trials used a wide range (acute 20 mg/kg; chronic 250 mg–2 g/day depending on formulation).. Best taken: Daily dosing in chronic trials; acute dosing used prior to exercise in one study (20 mg/kg).. Upper / caution level: Not established from provided trials..
What are the side effects of Carnosine?
Reported side effects include: No major adverse effects reported in the provided abstracts; detailed safety data limited in these reports.. Monitoring: None specified in the trials; consider monitoring for expected clinical endpoints if used for glycaemic control or performance.
Does Carnosine interact with medications?
Known or theoretical interactions: Not reported in the provided abstracts.. Always check with a clinician before combining with prescription medication.
Who should avoid Carnosine?
Carnosine is generally not recommended for: Pregnant or breastfeeding individuals due to limited safety data.; and Insufficient data in pregnancy and breastfeeding; not established in paediatric populations..
How strong is the evidence for Carnosine?
Evidence level: Moderate (overall score 57/100), based on 5 indexed studies on SuppIndex.
Research & References (5)
Effect of carnosine supplementation on lipid profile, fasting blood glucose, HbA1C and insulin resistance: A systematic review and meta-analysis of long-term randomized controlled trials.
Systematic review and meta-analysis of four RCTs (total n≈184) examining carnosine supplementation effects on glycaemic and lipid markers.
Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4.
12-week randomized, double-blind, placebo-controlled trial of combined anserine (750 mg) and carnosine (250 mg) daily in 54 subjects with mild cognitive impairment.
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
Placebo-controlled randomized trial (n=299) of 2 g/day carnosine over ~12 weeks assessing multiple physical performance measures.
Effect of Anserine/Carnosine Supplementation on Verbal Episodic Memory in Elderly People.
Double-blind RCT of anserine/carnosine (3:1, 1.0 g daily) for 3 months in 39 healthy elderly volunteers assessing cognitive tests and inflammatory markers.
Does low serum carnosinase activity favor high-intensity exercise capacity?
Cross-sectional observation of serum carnosinase and a double-blind placebo-controlled crossover trial (n=12) testing acute oral carnosine (20 mg/kg) before high-intensity cycling.
Related Ingredients
Other top-rated ingredients in Ergogenic Compounds.
Creatine Monohydrate
94/100A naturally occurring nitrogenous organic acid that facilitates recycling of adenosine triphosphate (ATP) in muscle and brain tissue via the phosphocreatine shuttle.
Maltodextrin
78/100Short-chain α-1,4 linked glucose polymer that is rapidly hydrolysed by brush-border maltase to glucose; near-equivalent glycaemic response to glucose but lower osmolality at concentration.
Cyclic Dextrin (HBCD)
72/100Produced via cyclic-glucanotransferase action on amylopectin, HBCD forms cluster-like macromolecules ~160 kDa that solubilise at low osmolality (≈4 mOsm/L) and clear the stomach faster than maltodextrin or glucose polymers.
Research Overview
Moderate EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/carnosine
SuppIndex. (2026). Carnosine: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/carnosine
Based on 5 indexed studies · Evidence level: Moderate.
Goal Ratings
Stack Compatibility
Many performance supplements target muscle carnosine through β-alanine; oral carnosine supplementation differs in pharmacokinetics because of serum carnosinase and may not substitute for β-alanine loading (insufficient direct evidence in the provided abstracts).